A excellent post SB. After approval of V for R-I (if successful), the hard work is still ahead. Which, of course, for a small company will be a gargantuan task.
SBsandman, I concede your point, but I think my point remains valid, the company needs to detail physician on Fibrates being withdrawn as add on treatment to Statin and recommend Vascepa. There 300K weekly Fibrate scripts to poach
CMS isn't helping either, they require prior authorizations for all Omega products including Vascepa, but not for fibrates. CMS also requires post treatment Trig numbers for Omega's, if your numbers drop below treatment goals does CMS stop paying for treatment? BB
Market Data 
Markets 
AI
